Lyra Therapeutics Inc (LYRA) Institutional Buying & Selling Tracker (Q2 2026)

LYRA ranks #31096 out of 37503 tracked stocks by institutional interest — a comparatively under-the-radar name outside the most closely tracked half.

Sabby Management, LLC has trimmed its LYRA position for two straight quarters, cutting it by $781.8K while still holding $51.1K.

LYRA reported a net loss of $28.9M over the trailing twelve months.

• Not yet profitable — net loss of $28.9M over the trailing twelve months
• Revenue declined 74.1% year over year
• Net income improved year over year, from -$93.4M to -$28.9M
• Operating cash flow was negative, using $28.9M in cash
• Current ratio of 1.71x — enough short-term assets to cover short-term liabilities
• Total liabilities currently exceed total assets (negative shareholder equity)